The Biotechnology Innovation Organization (BIO) has elected John Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals, the new Chair of its Board of Directors for the 2017-2018 term.
“We are excited for this new chapter of BIO with John at the helm,” said BIO President and CEO Jim Greenwood. “He brings both a scientific background and a passion for ensuring that breakthrough research is transformed into medicines, therapies and other products that can truly change people’s lives. He is keenly aware that educating the public and policy makers is the best way to ensure that effective therapies reach the marketplace.
Maraganore has served on BIO’s board for over a decade and has spent time as the chair of the Emerging Companies Section and as a co-chair of the Regulatory Environment Committee.
“I am honored and privileged to be selected for this important role,” said Maraganore. “My belief in the importance of BIO’s mission will guide me through my tenure. This industry has so much to offer and I will make every effort to ensure we are able to deliver.”
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development healthcare, agricultural, industrial and environmental biotechnology products.